Back to Previous Page
Binh Dinh Pharmaceutical and Medical Equipment (DBD VN) – Q1 2026 – Oncology and Dialysis Drive Growth Outlook
Summary of Q1 2026 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN)
- Net revenue rose 1.6% y/y to VND448bn. Growth was led by kidney dialysis products (+11.8% y/y), minerals, vitamins & supplements (+29.4% y/y), and psychiatric & neurological disorder therapies (+20.5% y/y). Oncology products (+1.5% y/y) and antibiotics (-15.2% y/y) lagged, as new competitor in the hospital channel led to more competitive tender pricing. Oncology was also partly affected by temporary production adjustments for EU-GMP upgrade works, while antibiotics faced short-term headwinds from stricter enforcement on prescription drug sales. Still, DBD maintained steady volume growth and broad coverage across ~2,000 hospitals nationwide, while pharmacy sales grew 6.9% y/y as market conditions improved after the 2025 transition period.
- Net profit edged down 0.9% y/y to VND80bn, as operating profit declined 7.4% y/y amid more competitive hospital-channel tender pricing. Nevertheless, DBD maintained disciplined cost control, with overall expenses rising broadly in line with production volume, keeping operating profit margin solid at 18.2%. Meanwhile, higher net financial income and income from associates helped cushion the overall impact on net profit.
- Vietnam’s pharmaceutical market continues to grow steadily, with demand shifting toward higher-value and specialized therapies. Recent data and market trends reaffirm stronger demand growth in specialized categories such as vaccines, oncology, cardiovascular, and metabolic treatments, while several conventional drug groups face slower growth due to saturation, competition, and limited pricing power. Policy support should further improve treatment access, as Vietnam targets universal health insurance coverage by 2030 and plans to expand the reimbursement drug list. In oncology, earlier diagnosis, a growing patient base, and potential biosimilar adoption should improve affordability and access to advanced treatments. This favors companies with improving manufacturing standards and deeper specialized portfolios like DBD.
- For the last 9M/2026, solid growth momentum across DBD’s product mix is expected to continue, alongside the oncology plant’s return to full operation, while antibiotics should recover as stricter prescription rules shift more volume to hospitals. Despite softer profit margin from more competitive hospital-channel tender pricing, lower expenses from the normalization of R&D-related cost allocation after last year’s high base should support FY2026 net profit to improve year-over-year. In the medium term, DBD’s growth is expected to accelerate, bolstered by new oncology tablet lines, ongoing new product development, EU-GMP certification for the oncology plant expected from 2027, and new capacity from the EU-GMP-certified aseptic injectable plant from 2029. Accordingly, we project a 21.0% 2027-2030 net profit CAGR. Meanwhile, the government’s priority for locally produced drugs, including those manufactured by foreign-invested local firm, continue to position DBD as a top acquisition target for international producers seeking a local foothold.
Interested in DBD? Click here to read more of our previous analysis on DBD’s quarterly earnings.
Read our latest insights in Vietnam Healthcare Sector here.
Company ratings and target prices are accessible for clients only.
If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.
Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.
Photo image credit: Bidiphar
